{"id":"https://openalex.org/W4362567153","doi":"https://doi.org/10.1158/2326-6066.22538645","title":"Tables S1 to S12 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma","display_name":"Tables S1 to S12 from VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362567153","doi":"https://doi.org/10.1158/2326-6066.22538645"},"language":"en","primary_location":{"id":"doi:10.1158/2326-6066.22538645","doi":"https://doi.org/10.1158/2326-6066.22538645","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.22538645","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2326-6066.22538645","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103093153","display_name":"Xinqi Wu","orcid":"https://orcid.org/0000-0003-4979-4596","observed_orcids":["https://orcid.org/0000-0003-4979-4596"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xinqi Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071788399","display_name":"Anita Giobbie\u2010Hurder","orcid":"https://orcid.org/0000-0003-2496-7737","observed_orcids":["https://orcid.org/0000-0003-2496-7737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anita Giobbie-Hurder","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100569863","display_name":"Xiaoyun Liao","orcid":"https://orcid.org/0009-0000-8904-0102","observed_orcids":["https://orcid.org/0009-0000-8904-0102"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoyun Liao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049839632","display_name":"Donald P. Lawrence","orcid":"https://orcid.org/0000-0001-5288-9110","observed_orcids":["https://orcid.org/0000-0001-5288-9110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald Lawrence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David McDermott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jun Zhou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jun Zhou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Rodig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9660000205039978},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9620000123977661},{"id":"https://openalex.org/keywords/vegf-neutralization","display_name":"VEGF neutralization","score":0.8019999861717224},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.9950000047683716},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.7540000081062317},{"id":"https://openalex.org/keywords/humoral-immune-response","display_name":"humoral immune response","score":0.7649999856948853},{"id":"https://openalex.org/keywords/icam-1","display_name":"ICAM-1","score":0.8849999904632568},{"id":"https://openalex.org/keywords/vcam-1","display_name":"VCAM-1","score":1.0},{"id":"https://openalex.org/keywords/cxcl10","display_name":"CXCL10","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cxcr3","display_name":"CXCR3","score":0.9620000123977661},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.8579999804496765},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":1.0},{"id":"https://openalex.org/keywords/serum-cytokines","display_name":"serum cytokines","score":0.890999972820282},{"id":"https://openalex.org/keywords/chemokines","display_name":"chemokines","score":0.8870000243186951},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8820000290870667},{"id":"https://openalex.org/keywords/tumor-immune-microenvironment","display_name":"tumor immune microenvironment","score":0.5730000138282776},{"id":"https://openalex.org/keywords/antibody-response","display_name":"antibody response","score":0.6069999933242798}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6972386240959167},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.6735950112342834},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.6062023043632507},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.6052495837211609},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5228003263473511},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5083908438682556},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.41727888584136963},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.347818523645401},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3091638386249542}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/2326-6066.22538645","doi":"https://doi.org/10.1158/2326-6066.22538645","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.22538645","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/2326-6066.22538645.v1","doi":"https://doi.org/10.1158/2326-6066.22538645.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.22538645.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2326-6066.22538645","doi":"https://doi.org/10.1158/2326-6066.22538645","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2326-6066.22538645","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362567375","https://openalex.org/W4362567141","https://openalex.org/W4362545969","https://openalex.org/W2514202874","https://openalex.org/W4362567125","https://openalex.org/W4405616821","https://openalex.org/W2939683703","https://openalex.org/W2964478944","https://openalex.org/W2887348851","https://openalex.org/W2590605191"],"abstract_inverted_index":{"Supplementary":[0,22,39,57,77,94,113,126,141,154,164,182],"Table":[1,23,40,58,78,95,114,127,142,155,165,183],"S1.":[2],"H-scores":[3],"of":[4,12,45,63,81,98,171,186],"ICAM-1,":[5],"VCAM-1":[6],"and":[7,16,30,35,169,189],"IP-10":[8],"expression":[9,26,124,139],"in":[10,74,110,134,178],"tumors":[11],"melanoma":[13],"patients":[14,136,172],"before":[15,34],"after":[17,36],"ipilimumab":[18,187],"or":[19],"Ipi-Bev":[20,37,121,190],"treatment.":[21,38],"S2.":[24],"CXCR3":[25],"on":[27,191],"circulating":[28,192],"CD4+":[29],"CD8+":[31],"T":[32],"cells":[33],"S3.":[41],"Pre-treatment":[42,60,144],"serum":[43,61,82,99],"levels":[44,62,146],"cytokines/chemokines":[46,64,83,100],"were":[47,65,84,101,176],"not":[48,66,85,102],"associated":[49,67,86,103],"with":[50,68,87,104],"response":[51,88,180],"(CR/PR":[52,89,117],"vs.":[53,72,90,108,118,132],"SD/PD/Uneval)":[54,91,119],"to":[55,92,120,148,162],"Ipi-Bev.":[56,93],"S4.":[59],"disease":[69,105],"control":[70,106,130],"(CR/PR/SD":[71,107,131],"PD/Uneval)":[73,109,133],"Ipi-Bev-treated":[75,111,135],"patients.":[76,112],"S5.":[79],"Fold-changes":[80,97],"S6.":[96],"S7.":[115],"Response":[116],"by":[122,137],"cytokine":[123,138,145,159],"category.":[125,140],"S8.":[128],"Disease":[129],"S9.":[143],"according":[147,161],"immune":[149],"related":[150],"adverse":[151],"events":[152],"(irAEs).":[153],"S10.":[156],"Relationship":[157],"between":[158],"fold-changes":[160],"irAEs.":[163],"S11.":[166],"Clinical":[167],"responses":[168],"survival":[170],"whose":[173],"plasma":[174],"samples":[175],"used":[177],"antibody":[179],"analyses.":[181],"S12.":[184],"Effects":[185],"alone":[188],"cytokine/chemokine":[193],"levels.":[194]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}